(MedPage Today) — The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced.
Aficamten is an allosteric and reversible inhibitor of cardiac myosin motor activity…
WhatsApp, training and tenecteplase injection bring heart attack care to rural Punjab
By combining WhatsApp-based coordination, training for frontline healthcare workers, and the clot-busting injection tenecteplase, doctors are improving access to timely...






